Literature DB >> 1346578

Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections.

G Juliusson1, J Liliemark.   

Abstract

Sixteen patients with symptomatic hairy cell leukemia were treated with a single course of 2-chloro-2'-deoxyadenosine (CdA), 0.7 mg/kg total dose. Twelve patients achieved complete remission (CR). One patient with a CD19+/CD5+/CD25- phenotype and one with a pentostatin-treated CD19+/CD25- variant form had minor responses. Two patients with advanced disease and poor performance status died early from invasive mycosis. Three patients recovered from infections caused by cytomegalovirus and by candida. No patient had infections caused by bacteria or by unknown organisms. The median time to full recovery from anemia and thrombocytopenia was 6 and 2 weeks from start of therapy, respectively. Patients with infections, however, recovered at 13 and 5 weeks, respectively. Neutrophil, monocyte, and lymphocyte counts returned to normal at a median of 5, 5, and 10 weeks, respectively. Infections developed more frequently in pancytopenic patients than in those with one or more blood cell count within the normal range (P less than .01). All patients with one or no previous therapy had a CR, whereas those with more than one previous regimen had a lower CR rate (P less than .01). Thus, 1 week of CdA therapy frequently induced CR also in patients resistant to interferon. Toxicity was limited, and recovery from cytopenia was faster than what is reported during interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346578

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Local application of antimycotics in mucormycosis cerebri: a case report.

Authors:  I Mohsenipour; M Schirmer; R Frank; F Geisen; E Semenitz; D zur Nedden; G Konwalinka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

2.  Phase II clinical study of cladribine in the treatment of hairy cell leukemia.

Authors:  Takashi Machii; Takaaki Chou; Muneou Suzuki; Yokiko Ohe; Shuichi Katagiri; E Kiyoshi Kitano; Kiyoshi Kitano; Yoshihide Fujiyama; Tooru Izumi; Chihiro Shimazaki; Koji Nanba; Yasuo Ohashi; Teruo Kitani
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 3.  Hairy cell leukaemia and venous thromboembolism: a case report and review of the literature.

Authors:  Natale Vazzana; Raffaele Spadano; Simona Sestili; Valentina Toto; Simona Falorio; Virginia Catinella; Francesco Angrilli; Alfredo Dragani
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

4.  Mechanisms behind hypocholesterolaemia in hairy cell leukaemia.

Authors:  G Juliusson; S Vitols; J Liliemark
Journal:  BMJ       Date:  1995-07-01

Review 5.  Hairy cell leukemia.

Authors:  Claire Dearden; Monica Else
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 6.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 7.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 8.  How I treat hairy cell leukemia.

Authors:  Michael R Grever
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

Review 9.  Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Authors:  H J Guchelaar; D J Richel; M R Schaafsma
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

Review 10.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.